Comparison of the systemic inflammatory response index and the systemic immune-inflammatory index in pediatric community-acquired pneumonia caused by respiratory syncytial virus and Mycoplasma pneumoniae

比较呼吸道合胞病毒和肺炎支原体引起的儿童社区获得性肺炎的全身炎症反应指数和全身免疫炎症指数

阅读:3

Abstract

OBJECTIVE: This study aims to compare the systemic inflammatory response index (SIRI) and the systemic immune-inflammatory index (SII) in pediatric community-acquired pneumonia (CAP) caused by the respiratory syncytial virus (RSV) and Mycoplasma pneumoniae (Mp). METHODS: The study included 120 children with single RSV infection (RSV group) and 120 children with single Mp infection (Mp group). The SIRI and SII were calculated by using the formulation neutrophil × monocyte/lymphocyte and platelet × neutrophil/lymphocyte, respectively. RESULTS: Significant differences were found between RSV and Mp infections in three age-stratified subgroups of <6 months, 3-5 years, and ≥5 years (p < 0.05). The proportions of children presenting with nasal stuffiness and rhinorrhea, shortness of breath, grunting, and gastrointestinal symptoms were markedly higher in the RSV group than those in the Mp group (p < 0.05). The RSV group had lower values of the SIRI and SII than the Mp group (p = 0.010; p = 0.021). The RSV group demonstrated significantly higher values in terms of duration of symptoms before admission, length of hospital stay, proportion of children requiring oxygen supplementation, and proportion of children with severe pneumonia compared with the Mp group (p < 0.05). The incidence of bronchial pneumonia and emphysema was significantly higher in the RSV group than that in the Mp group (p = 0.005; p = 0.001). However, the incidence of patchy shadow was significantly higher in the Mp group than that in the RSV group (p = 0.027). CONCLUSION: The SIRI and SII may offer additional value in differentiating CAP associated with RSV and Mp infections in children; both indices may serve as easily accessible blood indicators for clinical decision-making in the management of pediatric CAP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。